Search research articles
Contact Us
Filters
Showing results (1-10 of 204) with videos related to
Page
of 21
Sort By:
Anti-Cancer Drug Design
|
November 1, 1990
DNA topoisomerase II as the primary target of anti-tumor anthracyclines
F Zunino, G Capranico
Cancer Chemotherapy and Pharmacology
|
January 1, 1986
Synthesis and antitumor activity of a platinum (II)-doxorubicin complex
F Zunino, G Savi, A Pasini
Biochemical Pharmacology
|
February 28, 2001
Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy
G Pratesi, P Perego, F Zunino
Biochemical Pharmacology
|
April 5, 2001
Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs
F Zunino, G Pratesi, P Perego
International Journal of Cancer
|
February 15, 1986
Comparison of doxorubicin-induced DNA damage in doxorubicin-sensitive and -resistant P388 murine leukemia cells
G Capranico, T Dasdia, F Zunino
Anti-Cancer Drugs
|
October 1, 1990
Different interaction of cisplatin and etoposide on in vivo and in vitro tumor systems
C Soranzo, G Pratesi, F Zunino
Anti-Cancer Drugs
|
December 1, 1990
Effect of tumor necrosis factor on human tumor cell lines sensitive and resistant to cytotoxic drugs, and its interaction with chemotherapeutic agents
C Soranzo, P Perego, F Zunino
Stem Cells (Dayton, Ohio)
|
July 1, 1995
Mechanism of action of DNA topoisomerase inhibitors
M Binaschi, F Zunino, G Capranico
Cancer Research
|
January 15, 1995
Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety
G Capranico, E Butelli, F Zunino
Cancer Research
|
November 1, 1986
Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells
G Capranico, C Soranzo, F Zunino
Page
of 21
Search research articles
Search
Showing results (1-10 of 204) with videos related to
Sort By:
Page
of 21
Anti-Cancer Drug Design
|
November 1, 1990
DNA topoisomerase II as the primary target of anti-tumor anthracyclines
F Zunino, G Capranico
Cancer Chemotherapy and Pharmacology
|
January 1, 1986
Synthesis and antitumor activity of a platinum (II)-doxorubicin complex
F Zunino, G Savi, A Pasini
Biochemical Pharmacology
|
February 28, 2001
Role of Bcl-2 and its post-transcriptional modification in response to antitumor therapy
G Pratesi, P Perego, F Zunino
Biochemical Pharmacology
|
April 5, 2001
Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs
F Zunino, G Pratesi, P Perego
International Journal of Cancer
|
February 15, 1986
Comparison of doxorubicin-induced DNA damage in doxorubicin-sensitive and -resistant P388 murine leukemia cells
G Capranico, T Dasdia, F Zunino
Anti-Cancer Drugs
|
October 1, 1990
Different interaction of cisplatin and etoposide on in vivo and in vitro tumor systems
C Soranzo, G Pratesi, F Zunino
Anti-Cancer Drugs
|
December 1, 1990
Effect of tumor necrosis factor on human tumor cell lines sensitive and resistant to cytotoxic drugs, and its interaction with chemotherapeutic agents
C Soranzo, P Perego, F Zunino
Stem Cells (Dayton, Ohio)
|
July 1, 1995
Mechanism of action of DNA topoisomerase inhibitors
M Binaschi, F Zunino, G Capranico
Cancer Research
|
January 15, 1995
Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety
G Capranico, E Butelli, F Zunino
Cancer Research
|
November 1, 1986
Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells
G Capranico, C Soranzo, F Zunino
Page
of 21